The world’s biggest drug maker, Pfizer, pleaded guilty to a criminal charge to settle allegations of improperly marketing 13 medicines “off label” — paying a record $2.3 billion fine. School of Law Professor Kevin Outterson, director of the Health Law Program and an authority on drug marketing law, says “off-label” promotion is a signficant problem for public health and the FDA.
“If companies can bypass the FDA and market drugs for unapproved uses, then our drug safety system has been seriously compromises.”
Contact Kevin Outterson, 617-353-3103, mko@bu.edu
